SCHEMBL525091

SCHEMBL525091

[CH]1[CH]NCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183864 0.88
SCHEMBL20183860 0.70
Hydrochloric Acid SCHEMBL7715636 0.62
SCHEMBL1783483 0.60 CXCR4 (0.60)
SCHEMBL13562 0.60
SCHEMBL770757 0.58
Bromide SCHEMBL9222450 0.58
Hydrochloric Acid SCHEMBL3413512 0.58
Hydrochloric Acid SCHEMBL15415090 0.58
Iodide SCHEMBL31112409 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151759-A1 HETEROCYCLIC COMPOUNDS AS PI3Kα INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
US-11976058-B2 Aromatic derivatives, preparation methods, and medical uses thereof BIOARDIS LLC (US) 2024-05-07 US disclosed
WO-2023239846-A1 HETEROCYCLIC COMPOUNDS AS PI3KΑ INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
WO-2023230262-A1 TRICYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS SYNNOVATION THERAPEUTICS, INC. (US) 2023-11-30 WO disclosed
US-20220169634-A1 AROMATIC DERIVATIVES, PREPARATION METHODS, AND MEDICAL USES THEREOF BIOARDIS LLC 2022-06-02 US disclosed
CN-108137505-B Nitrogen-containing heterocyclic compound 富士胶片株式会社 2021-07-06 CN disclosed
US-10987349-B2 Antitumor agent and bromodomain inhibitor FUJIFILM CORPORATION (JP) 2021-04-27 US disclosed
EP-3563851-B1 ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR FUJIFILM CORP (JP) 2021-04-21 EP disclosed
CN-111902400-A Aromatic derivatives, process for their preparation and their medical use 保仕健生物科技(上海)有限公司 2020-11-06 CN disclosed
EP-3327004-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND FUJIFILM CORP (JP) 2020-11-04 EP disclosed
US-20020052417-A1 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-05-02 US disclosed
EP-1189929-A2 FACTOR VIIA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2002-03-27 EP disclosed
WO-2001094301-A2 FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-13 WO disclosed
EP-1162194-A1 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use Aventis Pharma Deutschland GmbH (DE) 2001-12-12 EP disclosed
EP-1066236-A4 PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE RES FOUNDATION OF (US) 2001-06-06 EP disclosed
EP-1066236-A1 PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE The Research Foundation of State University of New York (US) 2001-01-10 EP disclosed
WO-2000075172-A2 FACTOR VIIa INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-14 WO disclosed
EP-1059302-A1 Factor VIIa inhibitors Aventis Pharma Deutschland GmbH (DE) 2000-12-13 EP disclosed
WO-1999050214-A1 PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1999-10-07 WO disclosed
US-5962744-A USING CATALYST COMPLEX CONTAINING TRANSITION METAL AND PHOSPHITE LIGAND THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 1999-10-05 US disclosed